Table 6.
Management of candidemia.
| Management | n (%) | |
|---|---|---|
| Species identified | 132 | (77.6) |
| Echocardiography | 90 | (52.9) |
| Ophthalmic exam | 35 | (20.6) |
| Empiric therapy | ||
| Fluconazole | 51 | (30.0) |
| Caspofungin | 41 | (24.1) |
| Anidulafungin | 18 | (10.6) |
| Micafungin | 13 | (7.6) |
| Lipid formulation of amphotericin B | 12 | (7.1) |
| Itraconazole | 5 | (2.9) |
| Voriconazole | 2 | (1.2) |
| Empiric therapy changed | 62 | (36.5) |
| Targeted therapy | ||
| Fluconazole | 31 | (18.2) |
| Voriconazole | 6 | (3.5) |
| Caspofungin | 10 | (5.9) |
| Anidulafungin | 3 | (1.8) |
| Micafungin | 3 | (1.8) |
| Lipid formulation of amphotericin B | 8 | (4.7) |
| Other | 1 | (0.6) |
| Antifungal duration (days, mean ± SD) | 16.64 | ±26.334 |
| Antifungal at least 14 days after first negative culture | 47 | (27.6) |
| Central venous catheter removed | 80 | (47.1) |
| Tip sent for culture | 67 | (39.4) |